logo
ProjectCompleted

Biological E

Sector: Commercial • Location: India

Source: International Finance Corporation (IFC)

Biological E Limited (BioE or the “Company”), based in Hyderabad, India, develops and manufactures vaccines which are supplied within India and to other developing and middle-income countries either directly or through supplies to United Nations Children’s Fund (UNICEF) and the Global Alliance for Vaccines and Immunizations (GAVI). The Company is World Health Organization (WHO) pre-qualified for t

Status
Closed
Sector
Commercial, Warehouse, Manufacturing (Industrial), Government, Hospital
Location
India
Updated
22 Jul 2026
Source
International Finance Corporation (IFC)

ConstructChat

Ask ConstructChat about Biological E

Pick a question to edit it, or write your own.

First answer free · no account

I am a

Project Information FAQ

Project Information

5 Q
The project “Biological E” is an infrastructure initiative in the Commercial sector, located in India. Taiyo aggregates data on it from International Finance Corporation (IFC).

Participants

Sponsoring Agency

Status

Original status

completed

Taiyo status

Closed

Taiyo last update

2026-07-22

Contact

Not available for this record.

Description

Description

Biological E Limited (BioE or the “Company”), based in Hyderabad, India, develops and manufactures vaccines which are supplied within India and to other developing and middle-income countries either directly or through supplies to United Nations Children’s Fund (UNICEF) and the Global Alliance for Vaccines and Immunizations (GAVI). The Company is World Health Organization (WHO) pre-qualified for the liquid pentavalent vaccine (LPV) and the Japanese encephalitis (JE) vaccine. In pharmaceuticals, the Company manufactures generic formulations for the Indian market. The Company is now aiming to scale up its product offerings to include a wider range of vaccines and is setting up new manufacturing facilities in Shameerpet, Hyderabad, India for these products (the “Project). Immunization prevents illnesses from vaccine-preventable diseases, thus aiding in prevention of disability and death, in addition to lowering costs of healthcare and preventing productivity losses due to these illnesses. India’s Universal Immunization Programme (UIP), introduced in 1985, has made great progress in expanding Routine Immunization (RI) coverage across the country, and today, it is one of the largest programmes of its kind in the world. The Project will support a research-driven mid-cap company to diversify its product range and increase access to good quality affordable vaccines in India and other developing countries, create direct and indirect jobs and increase manufacturing capacity in India.

Original sector

G-FA - Pharmaceuticals and Medicine

Budget

Location

Country

India

Source

Source

International Finance Corporation (IFC)

URL

More Details

Record type

Project

Sector

Commercial, Warehouse, Manufacturing (Industrial), Government, Hospital

Article published date

2025-09-10

More on this project

Research

Free account

View all details

You are reading the public part. A free account opens the rest:

  • Every detail on this project
  • News and media coverage
  • Technical research
View all details

Free account · no card · lands you back on this project